When Shiley Inc. and its parent Pfizer pulled the Björk-Shiley Convexo-Concave (BSCC) heart valve from the world market in 1986, the device had been sold for seven years as a refinement of an already trusted prosthesis — and the refinement was the thing that killed people. Co-invented by American engineer Donald Shiley and the Swedish cardiac surgeon Viking Björk, the convexo-concave disc was a geometric tweak meant to improve blood flow over the company’s well-regarded flat-disc tilting valve. To make the new geometry work, the outlet strut that captured the swinging disc was changed and welded to the valve ring. That weld was the flaw. Under the relentless cyclic load of roughly 40 million heartbeats a year, the strut fractured at the weld, the disc escaped, and the valve failed catastrophically — often producing sudden death before the patient could reach an operating room.
The harm was not a rare anomaly tolerated by an unlucky few. Of the roughly 86,000 convexo-concave valves implanted worldwide, more than 600 are documented to have fractured, and in approximately two-thirds of those cases the patient died. The 60-degree version received U.S. Food and Drug Administration approval in 1979; a higher-flow 70-degree variant was sold abroad but never cleared in the United States, and it fractured at even higher rates. Because the failure mode was a fatigue crack that gave no reliable warning, surgeons and patients spent the late 1980s and 1990s trapped in an excruciating calculus: a working valve might snap tomorrow, but elective re-operation to remove it carried its own mortality.
What turned a metallurgical defect into a scandal was the factory. Sworn testimony and a 1984 engineer’s complaint described a Shiley plant in Irvine, California where valves rejected by inspectors were fished back out, reground to hide cracked welds, renumbered, and passed with falsified paperwork — welders were poorly trained, equipment was in “horrible” condition, and struts were forced onto flanges with pliers. The legend of an improved valve concealed a manufacturing line that could not reliably make the one weld on which a patient’s life depended. Litigation, not the FDA, ultimately fixed the price: the Bowling v. Pfizer class action settled in 1992 for roughly $215 million, with a further fund earmarked for future fracture claims, while implanted patients carried the device — and the fear — for the rest of their lives.
When Medtronic Inc. suspended distribution of the Sprint Fidelis defibrillator lead on 15 October 2007, the gap between what the device promised and what it delivered was already measured in patients shocked awake by a machine guarding a heart that never faltered — and in others whose hearts stopped while a fractured wire stood silent. The Fidelis (models 6930, 6931, 6948, 6949) had been marketed since September 2004 as a refinement of an unglamorous component: the insulated wire that carries the sensing and high-voltage shock between an implantable cardioverter-defibrillator and the heart muscle. Its selling proposition was caliber. At 6.6 French — roughly 2.2 millimeters — it was the thinnest defibrillation lead on the market, slimmer than Medtronic’s own proven Sprint Quattro and easier to thread into the right ventricle. Thinner was sold as better. Thinner was the defect.
The harm took two mirror-image forms. When a Fidelis conductor fractured — and the thin, integrated cables fractured at higher-than-baseline rates near the can and the anchor sleeve — the lead generated electrical noise the ICD misread as a lethal arrhythmia, and the device did what it was built to do: it delivered a 30-to-40-joule shock into a fully conscious patient, sometimes dozens of times in a night. The opposite failure was worse. A fractured conductor could also break the circuit, so that when the patient genuinely arrested, the defibrillator could not deliver the therapy that was its entire reason to exist. Medtronic’s own analysis projected roughly 2.3 percent of leads fracturing within 30 months; independent center series ran far higher, near 3.75 percent per year against 0.6 percent for comparison leads. At least 13 deaths were ultimately linked to the lead.
Medtronic halted sales and recalled all unimplanted Fidelis leads; the FDA designated it Class I, its most serious category, reserved for products that may cause serious injury or death. But the defining feature was what did not happen: the roughly 268,000 leads already inside patients’ chests were largely left there. A defibrillator lead becomes encased in scar and bonded to the heart wall within months, and extraction can tear the vena cava or ventricle and kill the patient on the table. The recall could not undo itself. Patients were handed a probabilistic dilemma — leave a wire with a known, accelerating failure rate, or accept the lethal risk of pulling it — and a management tail that fell heavily on Medicare. A 2010 settlement of roughly 8,100 lawsuits for $268 million closed the litigation; it did not close the chests.
When Guidant Corporation issued its physician advisory on June 17, 2005 and the FDA classified it a Class I recall — the most serious category, reserved for defects with a reasonable probability of serious injury or death — the gap between the device’s promise and its performance had already been measured in a single funeral. The Ventak Prizm 2 DR (Model 1861) was an implantable cardioverter-defibrillator, a machine whose entire purpose is to deliver a life-saving shock at the instant a patient’s heart fibrillates. Guidant had known since February 2002 that a fraction of these units were prone to internal electrical arcing — a short-circuit across degraded insulation that could render the device inert exactly when it was called upon to fire. The company quietly re-engineered the device in November 2002 to fix the flaw, then told the FDA the change did not affect safety or effectiveness, and continued shipping the older, defect-prone inventory it had already built.
The concealed defect became a body on March 14, 2005, when Joshua Oukrop, a 21-year-old college student from Grand Rapids, Minnesota, with hypertrophic cardiomyopathy, collapsed and died on a mountain-biking trip in Utah. His implanted Prizm 2 DR had short-circuited and failed to shock him. His electrophysiologists, Dr. Robert Hauser and Dr. Barry Maron of the Minneapolis Heart Institute, asked Guidant what had happened; the company disclosed that it knew of the failure mode but had no plan to warn physicians. Hauser and Maron took the case to The New York Times, whose reporter Barry Meier published it on May 24, 2005. Public exposure, not the manufacturer’s conscience, forced the recall three days later.
The reckoning was not regulatory but criminal. After a four-year investigation, the U.S. Department of Justice charged Guidant — by then a subsidiary of Boston Scientific, which had acquired it for roughly $27 billion in April 2006 — with making a materially false statement to the FDA about the Prizm 2 DR and failing to report a “correction” to its Contak Renewal defibrillators. Guidant pleaded guilty, and on January 12, 2011 U.S. District Judge Donovan W. Frank in St. Paul ordered it to pay more than $296 million in fines and forfeiture and serve three years of supervised probation — at the time the largest criminal penalty ever imposed for violating the Food, Drug, and Cosmetic Act. The episode became the foundational case for the principle that withholding a known device defect from regulators is not a paperwork lapse but a prosecutable crime.
When St. Jude Medical stopped selling its Riata and Riata ST defibrillator leads in December 2010 — eleven months before the FDA would classify the action as a Class I recall on 28 November 2011 — the gap between the device’s premise and its behavior was already a matter of cardiac geometry: a lead engineered to carry high-voltage shocks reliably for the life of an implantable cardioverter-defibrillator (ICD) was instead destroying itself from the inside out. The silicone insulation that sheathed the inner cabling abraded against the conductors it was meant to protect, and the high-voltage wires worked their way through the insulation and externalized — poked out of the lead body — inside the patient’s veins and heart. By the time sales stopped, more than 227,000 Riata-family leads had been distributed worldwide, roughly 79,000 of them still implanted in living U.S. patients, each one a wire that could fail to deliver a defibrillation shock at the one moment it was needed.
The danger of the Riata defect was not that it failed loudly but that it failed silently and electrically. A lead with externalized conductors could pass a routine pacing check on a clinic telemetry interrogation and still be incapable of completing a defibrillation circuit when a patient’s heart fibrillated. The mechanism was an electrical short between the superior-vena-cava and right-ventricular shock coils — the kind of fault that does not announce itself until the device must actually defibrillate, and then does not. Imaging studies later found externalized conductors in roughly 19 to 27 percent of Riata leads examined, with the thicker 8 French models worse than the 7 French Riata ST, and meta-analysis tied externalization to a more than six-fold rise in electrical abnormality.
The Riata story is less a tale of a single catastrophic flaw than of how long a known reliability problem can travel before regulation catches it. The leads had been on the market since 2001–2002; St. Jude withdrew them commercially in December 2010 in favor of its newer Durata lead, which carried an Optim co-polymer coating the company argued would resist abrasion. Only in late 2011 — after a Minneapolis Heart Institute cardiologist, Dr. Robert Hauser, mined the FDA’s MAUDE adverse-event database and published a series linking the Riata family to roughly 22 deaths from high-voltage shorting — did St. Jude issue the formal physician advisory the FDA then classified as Class I. St. Jude disputed Hauser’s death count and demanded a retraction; the underlying signal stood. As with Medtronic’s earlier Sprint Fidelis leads, the medical response was overwhelmingly to monitor in place rather than extract, because pulling a scarred-in lead from the heart carries its own mortal risk: at least two of the deaths in the recall record came not from the defect but from the extraction.
When Telectronics Pacing Systems issued a voluntary worldwide recall of its Accufix atrial “J” pacemaker leads on November 3, 1994 — a recall the U.S. Food and Drug Administration classified as Class I, its most severe category, reserved for products with a reasonable probability of causing serious injury or death — the device had already been doing precisely that. The Accufix lead carried, just behind its J-shaped tip, a thin metal “retention wire” whose only job was to hold the curve that anchored the electrode in the right atrial appendage. That wire fractured from metal fatigue, and the broken end could protrude through the lead’s polyurethane insulation and lacerate the atrial wall, the great vessels, even the aorta. The feature engineered to keep the lead in place became the mechanism that perforated the heart.
The gap between the design intent and the delivered harm was unusually stark because the failure was not rare. Radiographic screening of recalled-population patients found definite retention-wire fracture in 22.4 percent of leads examined, with the incidence climbing toward 25.6 percent on re-evaluation; the multicenter study put the fracture risk at roughly 5.6 percent per year. Roughly 45,000 leads had been implanted worldwide — about 25,000 of them in U.S. patients — across models 330-801 and 329-701. By the time of recall, Telectronics had logged two deaths and two non-fatal injuries; the worldwide registry would eventually record 40 spontaneous injuries, including 19 pericardial tamponades and six deaths.
What made the Accufix case distinct from a simple defective-device story was the trap it set after withdrawal. The lead could not simply be swapped like a battery: it was screwed into beating cardiac tissue and scarred in by years of healing. Extraction was itself lethal — fatal complications occurred in 0.4 percent of intravascular extraction procedures, 16 deaths among 4,023 attempts. Patients and cardiologists faced a documented dilemma with death on both arms: leave a fracturing wire in the heart and accept an annual protrusion risk, or pull it and accept an extraction-mortality risk that, for many low-fracture-risk patients, exceeded the hazard of leaving it alone. Telectronics funded the Accufix Research Institute to run the registry and study that quantified that trade-off, then exited the pacing business; the U.S. litigation consolidated as MDL-1057 and resolved in a settlement establishing a $58 million medical-monitoring and claims fund.